Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Clinical Lymphoma Myeloma and Leukemia（2019）
摘要
Our data support further investigation of indatuximab ravtansine as part of a combination regimen for relapsed and/or refractory MM.
更多查看译文
关键词
Antibody-drug conjugate,CD138,Monoclonal antibody,Multiple-dose,Syndecan-1
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要